Research programme: small molecules therapeutics - Kojin Therapeutics
Latest Information Update: 22 Jun 2021
At a glance
- Originator Kojin Therapeutics
- Class Anti-ischaemics; Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action Ferroptosis modulators; Ferroptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Fibrosis; Immunological disorders; Ischaemia; Neurodegenerative disorders
Most Recent Events
- 09 Jun 2021 Early research in Ischaemia in USA (unspecified route) (Kojin Therapeutics website, June 2021)
- 09 Jun 2021 Early research in Neurodegenerative disorders in USA (unspecified route) (Kojin Therapeutics website, June 2021)
- 09 Jun 2021 Early research in Cancer in USA (unspecified route) (Kojin Therapeutics website, June 2021)